Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Healthcare Shares
Can Opthea Ltd (ASX:OPT) be the next Cochlear Limited (ASX:COH)?
Growth Shares
Where I would invest $5,000 in the share market
Defensive Shares
3 high quality blue chips I want to buy
Share Market News
Big brands are in danger from cheap competition: Shares to avoid
Share Market News
No one is paying attention to this rising threat to the S&P/ASX 200 bull market
Growth Shares
These healthcare shares could be great long term investments
Share Market News
Why another top broker just upgraded Primary Health Care Limited (ASX:PRY) to "buy"
Share Market News
5 things to watch on the ASX on Monday
Share Gainers
Goldmans slaps buy rating and $16.70 share price target on ResMed Inc. (ASX:RMD)
Share Market News
How I'm preparing for the next financial crisis
Cheap Shares
Morgans tips Telstra (ASX:TLS) and 2 others as best value shares to buy
Share Market News
Donald Trump threatens to put a $200 billion bomb under share markets
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
